P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Glioblastoma is a highly aggressive brain tumor with a poor prognosis.
• Current treatments for glioblastoma are limited, necessitating novel therapeutic strategies.
• Chimeric antigen receptor (CAR) T cell therapy shows promise but faces challenges like tumor heterogeneity and antigen loss.

Purpose of the Study:

• To identify a suitable tumor-associated antigen for CAR T cell therapy in glioblastoma.
• To evaluate the efficacy of CAR T cells targeting the identified antigen.

Main Methods:

• Identification of p32/gC1qR/HABP/C1qBP as a surface antigen on glioma cells.
• Generation of p32-specific CAR T cells.
• In vitro assessment of CAR T cell cytotoxicity against glioma cells and tumor endothelial cells.
• In vivo evaluation of p32 CAR T cells in orthotopic syngeneic and xenograft mouse models.

Main Results:

• p32 was confirmed as specifically expressed on the surface of glioma cells.
• p32 CAR T cells demonstrated specific recognition and elimination of p32-expressing glioma cells and tumor-derived endothelial cells in vitro.
• p32 CAR T cells effectively controlled tumor growth in preclinical glioblastoma mouse models.

Conclusions:

• p32 is a viable target antigen for glioblastoma immunotherapy.
• p32 CAR T cells exhibit potent anti-tumor activity against glioblastoma.
• p32 CAR T cells represent a promising therapeutic strategy for glioblastoma patients.